Abstract:Hepatitis B virus (HBV) chronically infects 296 million people worldwide and causes more than 820,000 deaths annually due to cirrhosis and hepatocellular carcinoma. Current standard-of-care medications for chronic hepatitis B (CHB) include nucleos(t)ide analogue (NA) viral DNA polymerase inhibitors and pegylated interferon alpha (PEG-IFN-α). NAs can efficiently suppress viral replication and improve liver pathology, but not eliminate or inactivate HBV covalently closed circular DNA (cccDNA). CCC DNA is the most stable HBV replication intermediate that exists as a minichromosome in the nucleus of infected hepatocyte to transcribe viral RNA and support viral protein translation and genome replication. Consequentially, a finite duration of NA therapy rarely achieves a sustained off-treatment suppression of viral replication and life-long NA treatment is most likely required. On the contrary, PEG-IFN-α has the benefit of finite treatment duration and achieves HBsAg seroclearance, the indication of durable immune control of HBV replication and functional cure of CHB, in approximately 5% of treated patients. However, the low antiviral efficacy and poor tolerability limit its use. Understanding how IFN-α suppresses HBV replication and regulates antiviral immune responses will help rational optimization of IFN therapy and development of novel immune modulators to improve the rate of functional cure. This review article highlights mechanistic insight on IFN control of HBV infection and recent progress in development of novel IFN regimens, small molecule IFN mimetics and combination therapy of PEG-IFN-α with new direct-acting antivirals and therapeutic vaccines to facilitate the functional cure of CHB.

Progress of RNAi Targeting The Host Genes for Treatment of Chronic HBV Infection

Progress in treating HBV by RNAi technologies

RNAi for Treating Hepatitis B Viral Infection

Inhibition of Hepatitis B Virus Gene Expression by Single and Dual Small Interfering RNA Treatment

Long-term RNA interference and its application to hepatitis B virus

RNA Interference Therapeutics for Chronic Hepatitis B: Progress, Challenges, and Future Prospects

Advantages of RNA Interference in Anti-hepatitis B Virus Therapy

RNA interference as a novel treatment strategy for chronic hepatitis B infection

MicroRNAs may solve the mystery of chronic hepatitis B virus infection.

Opportunities for treating chronic hepatitis B and C virus infection using RNA interference

RNA Interference inhibits Hepatitis B Virus of different genotypes in Vitro and in Vivo

Inhibition of Hepatitis B Virus Replication by Various RNAi Constructs and Their Pharmacodynamic Properties

[Post-transcriptional regulation mechanism and antiviral strategy of hepatitis B virus RNA]

Mechanism of interferon alpha therapy for chronic hepatitis B and potential approaches to improve its therapeutic efficacy

Evaluation of Interfering RNA Efficacy in Treating Hepatitis B: Is It Promising?

Inhibition of Hepatitis B Virus Replication by Stably Expressed Shrna

Development of novel therapeutics for chronic hepatitis B

Progress in Anti-Hbv Infection Research by RNA Interference

Novel mechanistic insights – A brand new Era for anti-HBV drugs

Emerging therapeutics and relevant targets for chronic Hepatitis B

Interferon and interferon-stimulated genes in HBV treatment